



Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Hiroyuki Okuzawa, Representative Director, President and CEO
(Code no.: 4568, Prime Market, Tokyo Stock Exchange)
Please address inquiries to Kentaro Asakura, Corporate Officer,
Head of Corporate Communications Department
Telephone: for media +81-3-6225-1126
for stock market participants +81-3-6225-1125

(Correction) Notice of Partial Correction to the FY2025 Q1 Financial Results Presentation

Tokyo, Japan (July 31, 2025) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) hereby announces that there have been some corrections to the FY2025 Q1 Financial Results Presentation, disclosed on July 31, 2025. There are no corrections to the previously released the Consolidated Financial Results for the First Three Months of the Year Ending March 31, 2026 and its Reference Data. The corrected document is available on our website:

https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025Q1_Financial_Results_Presentation_E_V2.pdf

1. Reason for Corrections

We are issuing corrections as it has been discovered that there are errors in a part of the contents disclosed in our previous announcement.

2. Details of Corrections (The areas marked by red dotted lines indicate the corrections)

Page 5: Revenue Graph deformation

Page 9: Incorrect labels conversion in Performance Graph


<Before corrections>

Revenue




Increased by 38.4 Bn JPY (Increased by 57.6 Bn JPY excl. forex impact)

(Bn JPY)



Performance



Q1 Global Product Sales Result **155.2 Bn JPY**
 YoY **+25.6 Bn JPY (+19.7%)** Progress vs Apr. Forecast **23.4%**

Maintained the No.1 New Patient Share across Major Countries and Regions

- ◆ HR positive, HER2 low or ultralow BC (chemo naïve)
 - Solid progress in market penetration in US; Maintained the No.1 New Patient Share
 - Indication launched in EU in Apr.
- ◆ HER2 low BC (post-chemo): Reimbursement started in public sector in France from Apr.
- ◆ Robust sales growth in China following NRDL enlistment* in Jan.
 - *HER2+ BC 2L, HER2 low BC (post-chemo)



Q1 Global Product Sales Result **5.3 Bn JPY**
 YoY **+5.3 Bn JPY (-%)** Progress vs Apr. Forecast **113.6%**

- ◆ HR positive and HER2 negative BC
 - Strong initial uptake in US and Japan
 - Updated annual forecast: Jul. forecast **21.6 Bn JPY** (vs Apr. forecast +16.9 Bn JPY)
 - Raised awareness of safety management such as stomatitis
 - Product launched in EU in Jun.
- ◆ EGFR-mutated NSCLC: Indication launched in US in Jun.
- ◆ NCCN guideline inclusion: NSCLC

AE: Adverse Event, BC: Breast Cancer, HR: Hormone Receptor, NCCN: National Comprehensive Cancer Network, NRDL: National Reimbursement Drug List, NSCLC: Non-Small Cell Lung Cancer

9


<After corrections>

Revenue




Increased by 38.4 Bn JPY (Increased by 57.6 Bn JPY excl. forex impact)

(Bn JPY)



Performance



Q1 Global Product Sales Result 155.2 Bn JPY
 YoY +25.6 Bn JPY (+19.7%) Progress vs Apr. Forecast 23.4%

Maintained the No.1 New Patient Share across Major Countries and Regions

- ◆ HR positive, HER2 low or ultralow BC (chemo naïve)
 - Solid progress in market penetration in US; Maintained the No.1 New Patient Share
 - Indication launched in EU in Apr.
- ◆ HER2 low BC (post-chemo): Reimbursement started in public sector in France from Apr.
- ◆ Robust sales growth in China following NRDL enlistment* in Jan.

*HER2+ BC 2L, HER2 low BC (post-chemo)



Q1 Global Product Sales Result 5.3 Bn JPY
 YoY +5.3 Bn JPY (-%) Progress vs Apr. Forecast 113.6%

- ◆ HR positive and HER2 negative BC
 - Strong initial uptake in US and Japan
 - Updated annual forecast: Jul. forecast 21.6 Bn JPY (vs Apr. forecast +16.9 Bn JPY)
 - Raised awareness of safety management such as stomatitis
 - Product launched in EU in Jun.
- ◆ EGFR-mutated NSCLC: Indication launched in US in Jun.
- ◆ NCCN guideline inclusion: NSCLC

AE: Adverse Event, BC: Breast Cancer, HR: Hormone Receptor, NCCN: National Comprehensive Cancer Network,
 NRDL: National Reimbursement Drug List, NSCLC: Non-Small Cell Lung Cancer

9